Life after tocilizumab given for giant cell arteritis: a patient survey and argument for re-treatment-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Life after tocilizumab given for giant cell arteritis: a patient survey and argument for re-treatment

Published:2024-01-01 Issue:2 Volume:8 Page:
ISSN:2514-1775
Container-title:Rheumatology Advances in Practice
language:en
Short-container-title:

Author:

Quick Vanessa¹²^ORCID,Benson Fran²,Mackie Sarah L³⁴^ORCID

Affiliation:

1. Rheumatology Department, Luton and Dunstable University Hospital, Bedfordshire Hospitals NHS Foundation Trust , Bedford, UK

2. PMRGCAuk Society , London, UK

3. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds , Leeds, UK

4. NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust , Leeds, UK

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/rheumap/advance-article-pdf/doi/10.1093/rap/rkae054/57262459/rkae054.pdf

Reference7 articles.

1. Relapse after cessation of weekly tocilizumab for giant cell arteritis: a multicentre service evaluation in England;Quick;Rheumatology (Oxford),2023

2. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis;Hellmich;Ann Rheum Dis,2020

3. Long term effect of tocilizumab in patients with giant cell arteritis: open label phase of the Giant Cell Arteritis Actemra (GiACTA) trial;Stone;Lancet Rheumatol,2021

4. Trial of tocilizumab in giant-cell arteritis;Stone;N Engl J Med,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP